Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.45 |
| ▸ | ACACA | Q13085 | 5/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830784 | 0.88 | MAPT (0.43) | ACACBACACAOPRM1OPRD1ALDH1A1 | |
| SCHEMBL8185383 | 0.80 | KDM4E (0.43) | ACACBACACAOPRM1OPRD1ALDH1A1 | |
| SCHEMBL11041084 | 0.78 | POLB (0.44) | ALDH1A1KDM4EMAPTHTTRAB9A | |
| SCHEMBL7807433 | 0.78 | KDM4E (0.55) | ACACBACACAOPRM1OPRD1ALDH1A1 | |
| SCHEMBL10133732 | 0.77 | TSHR (0.50) | OPRM1OPRD1ALDH1A1OPRK1L3MBTL1 | |
| SCHEMBL3693246 | 0.75 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL9267594 | 0.74 | LMNA (0.63) | MAPTRAB9ALMNA | |
| SCHEMBL4597702 | 0.72 | KDM4E (0.62) | ACACBACACAOPRM1OPRD1ALDH1A1 | |
| SCHEMBL10774498 | 0.71 | POLB (0.66) | ALDH1A1MAPTHTTRAB9AMEN1 | |
| SCHEMBL196260 | 0.70 | KMT2A (0.51) | ALDH1A1KDM4EMAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041684-B2 | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6617347-B1 | Substituted pyrazoles are treatment of Type II diabetes and obesity. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-20020165234-A1 | Selective B3 adrenergic agonists | CROWELL THOMAS A (US) | 2002-11-07 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-0827746-B1 | Carbazole analogues as selective beta3 adrenergic agonists | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-6093735-A | TREATMENT OF TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| US-6075040-A | OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2000-06-13 | — | — | US | disclosed |
| US-5977154-A | OBESITY, DIABETES | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5939443-A | ANTIDIABETIC AGENTS AND TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1999029673-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| EP-0921120-A1 | Selective beta 3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5840738-A | Selective β-3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| US-5808080-A | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5786356-A | TREATING TYPE II DIABETES, OBESITY | ELI LILLY AND COMPANY (US) | 1998-07-28 | — | — | US | disclosed |
| WO-1998009625-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1997010825-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
| EP-0764640-A1 | Selective beta3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1997-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | ACACB 1019/4885ACACA 924/4885OPRM1 80/4885 |
| US-20020165234-A1 | Selective B3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | ACACB 963/4885ACACA 1191/4885OPRM1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.